Praxis to Present First Positive Phase 3 Data for Essential Tremor Drug at AAN 2026

Event summary

  • Praxis Precision Medicines will present data from the Phase 3 Essential3 program for ulixacaltamide, the first positive Phase 3 program in essential tremor, at the AAN 2026 Annual Meeting.
  • Ulixacaltamide has received FDA Breakthrough Therapy Designation based on Essential3 study results.
  • Praxis will deliver 15 scientific presentations at AAN 2026, including a plenary session on Essential3 results.
  • Essential tremor affects approximately 7 million people in the United States, with limited effective treatment options.
  • The plenary presentation on Essential3 results is scheduled for April 21, 2026, at 9:15 AM CT.

The big picture

Praxis Precision Medicines is positioning itself as a leader in CNS precision neuroscience, leveraging genetic insights to develop therapies for movement disorders and epilepsy. The presentation of Essential3 data at AAN 2026 underscores the company's focus on addressing unmet needs in essential tremor, a condition affecting millions. The strategic emphasis on precision medicine and the FDA's Breakthrough Therapy Designation highlight the potential for ulixacaltamide to become a first-in-class treatment.

What we're watching

Regulatory Pathway
Whether the FDA Breakthrough Therapy Designation will accelerate ulixacaltamide's approval process for essential tremor.
Market Potential
The commercial viability of ulixacaltamide in a market with limited treatment options for essential tremor.
Pipeline Progress
The pace at which Praxis can advance its broader CNS pipeline, including elsunersen and vormatrigine.